Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy. We describe a case of a 30 year old female with hypoplastic myelodysplastic syndrome and PNH. After two years of treatment with eculizumab, she became pregnant. She developed breakthrough hemolysis at 20 weeks gestation. Pharmacokinetic and pharmacodynamic studies demonstrated a subtherapeutic eculizumab level with absence of complement blockade. Escalation of her eculizumab dose successfully controlled hemolysis and restored therapeutic eculizumab level and activity. She delivered a healthy baby at 36 weeks.

Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalLeukemia Research Reports
Volume4
Issue number1
DOIs
StatePublished - 16 May 2015
Externally publishedYes

Keywords

  • Breakthrough PNH hemolysis complicating pregnancy
  • Escalated eculizumab dosing

Fingerprint

Dive into the research topics of 'Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis'. Together they form a unique fingerprint.

Cite this